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A major hallmark of prion diseases is the cerebral amyloid accumulation of the pathogenic PrPSc, an abnormally misfolded, protease-resistant,
and β-sheet rich protein. PrP106–126 is the key domain responsible for the conformational conversion and aggregation of PrP. It shares important
physicochemical characteristics with PrPSc and presents similar neurotoxicity as PrPSc. By combination of fluorescence polarization, dye release
assay and in situ time-lapse atomic force microscopy (AFM), we investigated the PrP106–126 amide interacting with the large unilamellar
vesicles (LUVs) and the supported lipid bilayers (SLBs). The results suggest that the interactions involve a poration-mediated process: firstly, the
peptide binding results in the formation of pores in the membranes, which penetrate only half of the membranes; subsequently, PrP106–126 amide
undergoes the poration-mediated diffusion in the SLBs, represented by the formation and expansion of the flat high-rise domains (FHDs). The
possible mechanisms of the interactions between PrP106–126 amide and lipid membranes are proposed based on our observations.
© 2007 Elsevier B.V. All rights reserved.Keywords: In situ time-lapse AFM; Supported lipid bilayers (SLBs); PrP106–126 amide; Semi-penetrated poration; Flat high-rise domains (FHDs)1. Introduction
The accumulation of amyloidogenic proteins is a common
feature observed in different human diseases, such as Alzhei-
mer's disease, Prion diseases, Parkinson's disease, and type 2
diabetes [1]. In the past decades, studies have demonstrated that
the amyloidogenic proteins can trigger cytotoxicities through
interacting with neuronal membranes and affecting their normalAbbreviations: PrPSc, scrapie PrP protein; PrPc, cellular PrP protein;
PrP106–126, K106TNMKHMAGAAAAGAVVGGLG126, numbered according
to the human PrP sequence; PrP106–126 amide, C-terminal amidation of
PrP106–126; SLBs, supported lipid bilayers; AFM, atomic force microscopy;
DPH, 1,6-diphenyl-1,3,5-hexatriene; LUVs, large unilamellar vesicles; MLVs,
multilamellar vesicles; ANTS, 1-aminonaphthalene-3,6,8-trisulfonic acid; DPX,
N,N′-p-xylylenebis (pyridinium) bromide; POPC, 1-Palmitoyl-2-Oleoyl-sn-
Glycero-3-Phosphocholine; Chl, cholesterol; PBS, phosphate-buffered saline;
HBS, HEPES-buffered saline; FHDs, flat high-rise domains
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doi:10.1016/j.bbamem.2007.03.003structures and functions. For example, the amyloid proteins/
peptides have been proven to change membrane fluidity [2,3],
induce the abnormal channel formation [4–7], produce free
radicals and cause the lipid peroxidation [8,9]. As the typical
fatal neurodegenerative disorders, Prion diseases are character-
ized by the cerebral amyloid accumulation of an abnormally
misfolded, protease-resistant, and β-sheet rich pathogenic iso-
form PrPSc (scrapie PrP), which is derived from the normal cell-
surface glycoprotein PrPc (cellular PrP)][10]. Current studies
have revealed that the hydrophobic domain (residues 111–134)
of PrP, as a type II signal-anchor sequence, can direct the
translocation of the C-terminus of PrP across the membrane to
produce the pathogenic CtmPrP (C-terminus transmembrane
PrP), which spans the lipid bilayer of the endoplasmic reticulum
membrane with its C-terminus located on the membrane-
extrinsic side [11,12]. However, little is known about how the
amyloidogenic PrP protein perturbs lipid membranes.
PrP106–126 (K106TNMKHMAGAAAAGAVVGGLG126,
numbered according to the human PrP sequence) is a highly
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and adjacent to the well-ordered globular domain of PrP. It plays
an important role in the conformational conversion and aggrega-
tion of PrP [13]. Because of the difficulties in isolating and
characterizing PrPSc, it is generally acceptable to use PrP106–126
as a substitute of PrPSc to study the physicochemical and
pathological properties of PrP [14]. As an alternative, PrP106–
126 peptide possesses many properties of PrPSc, including the
partial protease resistance, the propensity to adopt β-sheet
conformation and form amyloid fibrils, as well as the ability to
induce the nerve cell degeneration in a number of different
primary cell cultures [15–18]. The primary structure of PrP106–
126 is characterized by two distinct regions, a hydrophilic region
(K106TNMKHM112) and a hydrophobic region (A113GAAAA-
GAVVGGLG126), which render a favorable condition for
interacting with cell membranes [4–6,15,19]. Interestingly, both
the amyloidogenicity and the neurotoxicity of PrP106–126 are
very sensitive to minor molecular modifications, such as
oxidation, chemically conformational stabilization, structural
relaxation and C-terminal amidation [20,21]. Although it is still
controversial whether PrP106–126 amide could cause the PrPc-
dependent neurotoxicity [20–22], the slow kinetics of the
fibrogenesis of PrP106–126 amide in physiological conditions
[23]makes it an idealmodel for studying its properties on the lipid
membranes by in situ time-lapse atomic forcemicroscopy (AFM).
In this work, we focused on the studies of PrP106–126
amide interacting with the mica-supported lipid bilayers (SLBs)
under aqueous conditions by in situ time-lapse AFM. SLB is a
broadly applied model system for the investigation of
membrane-related processes, e.g. cell adhesion [24], drug–
membrane interactions [25] and protein–membrane interactions
[26–33]. Our results demonstrate that PrP106–126 amide
induced the distinctive semi-penetrated poration in the SLBs;
subsequently, the flat high-rise domains (FHDs) were formed
due to the diffusion of the peptide into the hydrophobic regions
of the lipid bilayers. It provides a new insight into the process of
PrP106–126 interacting with lipid membranes. The possible
mechanisms of PrP106–126 amide interacting with lipid
bilayers are proposed based on our results.2. Materials and methods
2.1. Chemicals
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine (POPC), cholesterol
(Chl) and 1,6-diphenyl-1,3,5-hexatrine (DPH) were purchased from Sigma-
Aldrich (USA). 1-aminonaphthalene-3,6,8-trisulfonic acid (ANTS) and N,N′-p-
xylylenebis (pyridinium) bromide (DPX) were purchased from Molecular
Probes (USA). Three different buffers were used for sample preparation and
AFM imaging: PBS (20 mM Na2HPO4, 5 mM NaH2PO4, 125 mM NaCl, 5 mM
KCl, pH 7.4); HBS1 (50 mMHEPES, 100 mMNaCl, 2 mMCaCl2, pH 7.4); and
HBS2 (50 mM HEPES, 100 mM NaCl, pH 7.4). All the buffers were filtered
through 0.2 μm filters prior to use. Ultrapure water (18 MΩ) was used for the
buffer preparations and the experiments.
2.2. Peptide preparation
PrP106–126 amide (H2N-KTNMKHMAGAAAAGAVVGGLG-CONH2)
was synthesized manually by the standard solid-phase synthetic strategy ofFmoc chemistry [34] on a scale of 0.2 mmol of Rink amide MBHA resin. After
the completion of the synthesis, the peptide resin was washed with ethanol and
dried. A cocktail of 2.5% ethanedithiol (EDT), 5% thioanisole, 5% phenol, 5%
H2O, and 82.5% trifluoroacetic acid (TFA) was used to cleave the peptide off the
resin and remove the side chain-protecting groups. The crude peptide was
purified by RP-HPLC (Gilson Inc., France). The identity of the peptide was
confirmed by matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) with a single peak observed ([M+H]+:
observed 1911.71/calc. 1911.3). The purity (>95%) was detected by using
analytical RP-HPLC. The PrP106–126 amide was dissolved in H2O at a
concentration of 2 mM and stored at −20 °C immediately. No aggregation was
observed when the stock solution thawed before the experiments.
2.3. LUVs preparation
The lipid was dissolved in chloroform/methanol (2:1, v/v) and dried in a
rotary evaporator and then kept under high vacuum overnight. Multilamellar
vesicles (MLVs) were prepared by adding 400 μl of the buffer into the bottle to
hydrate the lipid at a concentration of 1.0 mg/ml, and then the solution was
vortexed vigorously until it became constantly milky. LUVs were prepared by
extrusion of the MLVs through a 0.1 μm polycarbonate membrane (Avanti Polar
Lipids) at 65 °C [29,35].
2.4. Fluorescence polarization measurements
The 1,6-diphenyl-1,3,5-hexatriene (DPH) solution in tetrahydrofuran
(2.6×10−4 mol/L) was added into the LUVs solution in PBS at a molar ratio
of 1:100 (probe: lipid), then the mixed solution was incubated at 25 °C for
30 min in dark. PrP106–126 amide solution was added to the DPH-labeled
LUVs at the final concentrations of 10 μM, 20 μM, 30 μM, 40 μM, and 50 μM,
respectively. The mixed solution was immediately incubated at 25 °C for 10 min
in dark and then the fluorescence polarization was measured. The measurements
were carried out on an F-4500 fluorescence spectrometer equipped with the
polarization accessories (Hitachi, Japan). The data were collected at 25 °C with
the excitation wavelength at 360 nm and the emission wavelength at 430 nm.
Both excitation and emission slits were set at 5 nm. The degree of fluorescence
polarization (P), which reflects the motion and viscosity of lipid molecules, was
calculated according to the following formula [36]: P=(IVV−GIVH) / (IVV+
GIVH), where IVVand IVH are the fluorescence intensities measured with parallel
and perpendicular oriented polarizers, respectively, and G is the calibration
factor. Here, G= IHV / IHH, V=0, H=0.
2.5. Permeability assay of the lipid vesicles
The LUVs were prepared as described in a mixed solution of 12.5 mM
ANTS, 45 mM DPX, 50 mM HEPES (pH 7.4) and 20 mM NaCl. The vesicles
were added onto a HiTrap™ desalting column and eluted with HBS2 to
remove the unencapsulated ANTS and DPX and then diluted to a concentration
lower than 100 μM. After 20 min of the PrP106–126 amide treatment, the
fluorescence intensities were recorded at 25 °C with the excitation wavelength
at 355 nm and the emission wavelength at 512 nm (F-4500 fluorescence
spectrometer, Hitachi, Japan). The fluorescence intensity corresponding to
100% leakage was determined by adding Triton X-100 (2.5%, v/v) into the
vesicles until the maximum intensity achieved.
2.6. Preparation of SLBs
2.6.1. Preparation of SLBs in PBS [29,35,37]
The LUVs solution was prepared as described by using PBS as the
hydrating solution. SLBs were prepared by the vesicle fusion method [37].
Briefly, 80 μl of the LUVs suspension was pipetted on the freshly cleaved mica
(8 mm in diameter) and incubated at 70 °C for 2 h in a water bath. The sample
was slowly cooled down to room temperature and then carefully rinsed with
PBS to remove the excessive LUVs and the loosely adsorbed bilayers. The
mounted bilayers were maintained in an aqueous environment. According to
our measurements, the prepared SLBs can be stable in PBS for several days at
room temperature.
Fig. 1. Effects of PrP106–126 amide on the membrane fluidities of POPC and
POPC/Chl (4:1, mol:mol) vesicles were measured by the fluorescence
polarization method using DPH as the probe. Polarization value (P) is
proportional to the molar concentration of the peptide according to the
following equations: For POPC LUVs, P=0.0029[C]+0.1339, R2=0.9815; for
POPC/Chl LUVs, P=0.0031[C]+0.1708, R2=0.9865.
Fig. 2. Leakage of the vesicle contents (ANTS/DPX) of POPC and POPC/Chl
(4:1, mol:mol) LUVs induced by different concentrations of PrP106–126 amide
at 25 °C. The lines on the graph are the trendlines vs. the peptide concentrations.
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Through the same procedure described in the above section, SLBs in HBS
were prepared by using HBS1 as the hydrating solution, and the mica covered by
the SLB was rinsed by HBS2.
POPC bilayers are in the liquid crystalline state at room temperature, and the
packing density is about 0.64 nm2 per lipid molecule [39]. So that the amount of
lipids on the mica surface (8 mm in diameter) is about 0.33 nmol if the prepared
SLBs didn't have any defect. Since the total volume of buffer used for the AFM
experiments is 100 μl, thus the lipid concentration on the mica surface is about
3.3 μM. Given that cholesterol packs into the acyl chains of the lipid bilayers as
a molecular spacer, the lipid concentration of the POPC/Chl SLBs should be
similar to that of the POPC SLBs.
2.7. Atomic force microscopy
AFM images of the solution-tapping mode were obtained on a multimode
atomic force microscope with a Nanoscope IV controller (Veeco Instruments,
USA) equipped with an EV-scanner. The sharpened OTR8 cantilevers (Veeco
Instruments) with a nominal spring constant at 0.15 N/m were used for the AFM
imaging. The frequency of the cantilever oscillation was tuned to 7–10 kHz and
the drive amplitude was adjusted to get the RMS value between 1.0 and 2.0 V.
The scan rate was set at 1.49 Hz. For the in situ time-lapse AFM experiments,
SLBs were first imaged with the solution-tapping mode to check the initial states
of SLBs before the PrP106–126 amide treatment. Then the PrP106–126 amide
solution was injected into the sample to make a final concentration of 25 μM and
the sample was scanned immediately at room temperature. During the
experiment, 20 μL of the buffer was injected into the imaging field every 2 h
to make up the evaporated liquid. All images were taken as 512×512 pixel scans
and were flattened and plane-fitted by the NanoscopeШ software (Ver. 5.12r2,
Veeco Instruments) before the data analysis. The height and depth were
measured by the “section” function and the percentage of FHDs area was
analyzed by the “bearing” function of the Nanoscope Ш software. The
percentage of the FHDs area was corrected by subtracting the area of pores. The
FHDs expansion as a function of time was calculated using the following
logistic function: y=a/[1+b*exp(−c*x)], in which y is the percentage of FHDs
area at the time of x min. Given the biological meanings of the functions (y is
zero at 0 min and the maximal percentage of FHDs area is 100%), we name
a=100 and b≥100 in this work.
3. Results
3.1. Membrane fluidity and permeability
In order to determine the effect of PrP106–126 amide on the
membrane fluidity, we performed fluorescence polarizationmeasurements using DPH as the probe. DPH can insert into the
hydrophobic region of the membrane and is widely used to
measure the order of the fatty acyl chains of the lipid bilayer.
The relative motion of the DPH molecules within the lipid
bilayer is determined by the polarization value P, which is
inversely proportional to the degree of the membrane fluidity.
As shown in Fig. 1, after 10 min of incubation with PrP106–126
amide at 25 °C, the fluidities of both POPC and POPC/Chl
LUVs decreased with the peptide concentrations increasing. It
suggests that PrP106–126 amide may insert into the hydro-
phobic regions of the lipid bilayers, therefore the motions of the
fatty acyl chains are restricted. Notably, the absolute fluidity of
POPC/Chl LUVs is always lower than that of POPC LUVs at
the same peptide concentrations. It is reasonable that cholesterol
molecules may insert into the intermolecular space of the POPC
lipids thus increase the packing density of the acyl chains of the
lipids and decrease the fluidity of the membrane [40–43].
To further assess the membrane perturbation induced by
PrP106–126 amide, the ANTS-DPX leakage experiments were
performed for both POPC and POPC/Chl LUVs based on the
fact that the fluorescence of ANTS can be quenched by DPX
within very short distances. The results show that the peptide-
induced leakage of POPC LUVs is greater than that of POPC/
Chl LUVs at the same peptide concentrations (Fig. 2). Typically,
for POPC LUVs, we observed 25% of leakage at a peptide
concentration of 100 μM, whereas the same amount of peptide
gave rise to only 6% of the leakage of POPC/Chl LUVs. It is
consistent with the fluidity assay and could be ascribed to the
role of cholesterol in stabilizing lipid assemblies [40–42,44].
3.2. AFM imaging of peptide–SLBs interactions
In situ time-lapse AFM experiments were carried out to
visualize the structural and morphological features of the mica
based SLBs in the presence of PrP106–126 amide. Two SLBs
model systems, POPC and POPC/Chl (4:1, mol/mol), were
investigated in two different buffers (PBS and HBS), respec-
tively. The averaged height of the SLBs is about 5 nm observed
by AFM (data not shown) and consistent with the data of other
groups [37,45].
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In Fig. 3, a set of in situ time-lapse images of the POPC SLB
interacting with PrP106–126 amide in 25 mM PBS was
presented. The SLB was first imaged to check the initial state
without the presence of the peptide (Fig. 3 at 0 min). After
injection of PrP106–126 amide, FHDs appeared on the SLB at
the sixth minute, which are higher than the surrounding lipid
bilayer (Fig. 3 at 6 min). They expanded in size laterally and
fused together gradually with the time prolonging, and took up
nearly 100% of the visual field at 60 min. The height difference
between the FHDs and the surrounding lipid bilayer is about
1.6±0.3 nm (n=11) [Fig. 3, section analysis (1)]. Strikingly,
there is a pore located in the middle of almost each formed
FHDs. The deepest depth of the pores on FHDs is about 4.4 nm
[Fig. 3, section analysis (2)]. Consequently, the relative depth of
the pore to the top surface of the SLB is only about 2.8±0.3 nm
(Fig. 8). Since the heights of POPC bilayer and the FHDs are
about 5 nm and 6.6±0.3 nm, respectively, thus the pores
probably penetrate through one leaflet of the bilayer. The
formed FHDs and pores were stable in the aqueous solution for
at least 1290 min (Fig. 3 at 1290 min), implying that the
formations of pores and FHDs are the dominant phenomena of
the peptide interacting with the SLB. In addition, we captured
two spots in the visual field (Fig. 3, indicated by black arrows),
which were presented on the top of the SLB surface prior to the
peptide treatment and remained at the same positions with the
same sizes throughout the experiment. Without the treatment of
the peptide, we didn't observe the FHDs and pores on the SLB
(data not shown). Taken together, we presume that the pores
may be associated with PrP106–126 amide inserting into the
membrane and the FHDs expansion is observed due to the
diffusion of PrP106–126 amide in the SLB.
Fig. 4 presents the PrP106–126 amide interacting with
POPC/Chl (4:1, mol/mol) SLB in PBS solution. The SLBFig. 3. In situ time-lapse AFM images of the diffusion of PrP106–126 amide in POP
10 nm. The image at 0 min represents the membrane without the presence of the pepti
PrP106–126 amide. The black arrows indicate the spots presenting on the SLB before
thermal effect of AFM imaging. Section analysis (1): FHDs are ∼1.6 nm higher than
analysis (2): the depth of the deepest pore on FHDs is about 4.4 nm along the blackporation and the FHDs formation and expansion were also
observed (Fig. 4). It seems that the pores were formed before the
FHD formation (Fig. 4b and b′). Interestingly, an original pore-
like structural “defect” on the SLB was observed before adding
PrP106–126 amide (Fig. 4a), and an FHD was formed round it
at the sixth minute upon the treatment of the peptide (Fig. 4a′).
Although it was rare to capture such a structural defect on SLBs,
this result, at least, implicates that the structural defect of
membranes could be a native starting point in mediating
PrP106–126 amide diffusion into SLBs. Similar to the pores
observed in the POPC SLB, the relative depth of the deepest
pore to the top surface of the POPC/Chl SLB is about 3.0±
0.1 nm (Figs. 4 and 8).
3.2.2. POPC and POPC/Chl SLBs in HBS
Due to the limitation of the scanning speed for AFM to
image a visual field, it was difficult to track the initial process of
the SLBs poration induced by PrP106–126 amide. However, in
the experiments, we found that HEPES buffer efficiently
decelerated the diffusion of the peptide in SLBs. It may be
because the zwitterionic HEPES molecules competitively
prohibit the electrostatic adsorption of PrP106–126 amide
onto the zwitterionic surface of lipid membranes. In HBS, we
were able to record the slower dynamics of the SLBs poration
induced by PrP106–126 amide.
As shown in Fig. 5, the pores were observed at 18 min after
adding the peptide. The formed FHDs are about 2.5±0.1 nm
(n=11) higher than the surrounding lipid bilayer [Fig. 5, section
analysis (1)]. After nearly 90 min, the FHDs expanded up to
nearly 100% of the visual field. The deepest pore on the HFDs is
about 5.2 nm in depth [Fig. 5, section analysis (2)], thus the
relative depth of the pore to the top surface of the POPC SLB is
about 2.7±0.1 nm (Fig. 8), similar to the pores observed in PBS
solution.C SLBs buffered by 25 mM PBS. The visual field is 10×10 μm. Height scale is
de. The white arrows indicate the FHD and the pore formed after the injection of
the treatment of PrP106–126 amide. The drift of the image is probably due to the
the surrounding lipid bilayer along the black line in the image of 18 min. Section
line in the image of 60 min.
Fig. 4. In situ time-lapse AFM images of PrP106–126 amide diffusion in POPC/Chl (4:1, mol/mol) SLBs buffered by 25 mM PBS. The visual field is 10×10 μm.
Height scale is 10 nm. The image at 0 min represents the membrane without the presence of the peptide. The black arrows indicate the original spots presenting on the
SLB before the treatment of PrP106–126 amide. (a), (a′), (b) and (b′) are zoomed in pictures from the corresponding regions shown in the upper panel. The circle in (a)
indicates a defect presenting on the SLB before the treatment of the peptide. (a) and (a′) display the defect-dependent FHDs formation. The circles in (b) and (b′)
indicate the peptide-dependant poration and FHDs formation. Section analysis (1): FHDs are∼2.0 nm higher than the surrounding lipid bilayer along the black line in
the image of 6 min. Section analysis (2): the depth of the deepest pore on FHDs is about 5.0 nm along the black line in the image of 30 min.
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in the 18-min picture (Fig. 5). There were some small sized
FHDs located near the pores, which grew up and fused into
larger FHDs as shown in the frame of the 24-min picture (Fig.
5). The similar phenomena have also been observed in the
experiment for the POPC/Chl SLB in PBS (Fig. 4b and b′).
Fig. 6 shows the PrP106–126 amide diffused into the
POPC/Chl (4:1, mol/mol) SLB in HBS. Pores appeared at
24 min and subsequently turned to be surrounded by the
small sized FHDs at 30 min (Fig. 6a and a′). The FHDs
expanded and fused together and took up the whole SLB areaFig. 5. In situ time-lapse AFM images of PrP106–126 amide diffusion in POPC SL
image at 0 min represents the membrane without the presence of the peptide. The whi
amide. The insets in 18 and 24 min are zoomed in pictures from the corresponding fra
126 amide. The rectangular frames indicate the destroyed regions on the SLB cau
surrounding lipid bilayer along the black line in the image of 36 min. Section analysis
the image of 90 min.after 60 min of the peptide treatment, whereas the pores
remained at the same positions (Fig. 6). The depth of the
deepest pore is about 3.1±0.2 nm (Figs. 6 and 8). Notably,
we found that the small sized FHDs could be formed in the
field without a pore (Fig. 6b), which also expanded with the
time prolonging. But the expansion rate of such FHDs is
much slower than that of the pore-mediated FHDs (Fig. 6b
and b′). Although this phenomenon was rare during the
experiments, it implies that the FHDs formation is possible
without the SLBs poration. In turn, they may promote the
poration (Fig. 6b, b′ and b′′). We assume this phenomenonB buffered by HBS. The visual field is 10×10 μm. Height scale is 10 nm. The
te arrows indicate the FHDs and pores formed after the injection of PrP106–126
mes. The square frames indicate the pores formed after the treatment of PrP106–
sed by the AFM tip. Section analysis (1): FHDs are ∼2.5 nm higher than the
(2): the depth of the deepest pore on FHDs is about 5.2 nm along the black line in
Fig. 6. In situ time-lapse AFM images of PrP106–126 amide diffusion in POPC/Chl (4:1, mol/mol) SLB buffered by HBS. The visual field is 10×10 μm. Height
scale is 10 nm. The image at 0 min represents the membrane without the presence of the peptide. Zoomed in pictures are shown in the lowest panel. (a) and (a′)
indicate the poration-based FHDs formation. (b), (b′) and (b′′) show a FHD formed prior to the pore formation. (b′′′) is the phase image of (b′′). Section analysis
(1): FHDs are ∼2.1 nm higher than the surrounding lipid bilayer along the black line in the image of 36 min. Section analysis (2): the depth of the deepest pore on
FHDs is about 5.2 nm along the black line in the image of 48 min.
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PrP106–126 amide into SLBs.
Interestingly, in both HBS and PBS buffers, the number of
pores formed in POPC/Chl SLBs is much more than that in
POPC SLBs (Figs. 5 and 6). Also, the expansion rate of
FHDs in POPC/Chl SLBs is quicker than that in POPC SLBs
(Fig. 7).Fig. 7. The expansion of FHDs as a function of time. The ordinate is the area
percentage of HFDs calculated from the visual field of the AFM imaging. The
abscissa is the time of PrP106–126 amide interacting with the SLBs. The 0 min
at the abscissa represents the membrane without the presence of the peptide. (•:
POPC in PBS, y=100/ (1+100*exp(−0.1588*x)), R2=0.9864; ○: POPC in
HBS, y=100/ (1+167.2*exp(−0.1034*x)), R2=0.9873;▪: POPC/Chl in PBS,
y=100 / (1+100*exp(−0.4387*x)), R2 =0.9994; □: POPC/Chl in HBS,
y=100/ (1+14440*exp(−0.2383*x)), R2=0.9999).4. Discussion
By combination of fluorescence polarization measurement,
dye release assay and in situ time-lapse AFM, we were able to
investigate the actions of PrP106–126 amide on the model
membranes. The results demonstrate that PrP106–126 amide
perturbs SLBs predominately through a poration-mediated
process. Similar phenomena have also been reported by the
studies of some antimicrobial peptides interacting with lipid
membranes [46].
4.1. Semi-penetrated pores formation
Currently, there are three proposed models about peptide-
induced poration in lipid bilayers: carpet model, barrel-stave
model, and toroidal model for α-helical antimicrobial peptides
[46–49]. In any case, the poration starts with the peptide
adsorption to the membrane surface that leads to a lateral
expansion of the membrane and a thinning of the hydrophobic
lipid core [50,51]. In order to reduce the strains imposed on
the bilayers by the peptides, the membrane systems with
different physicochemical characteristics will respond in dif-
ferent ways.
By in situ time-lapse AFM, we directly observed the
porations induced by PrP106–126 amide in the different
SLBs (Figs. 3–6). However, the pores formed could not
penetrate through the membranes and the deepest depth of the
pores is only about half of the thickness of the lipid bilayer. So
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49], in which the peptide induced pores can penetrate through
the lipid bilayers. The depths of the pores resulted from
PrP106–126 amide in the different SLBs are summarized in
Fig. 8, revealing the higher depths of pores are related to the
thicker membranes caused by the cholesterol packing into the
acyl chains of the lipids.
As an amphiphilic peptide, PrP106–126 amide has the
potential to associate with POPC bilayers and form peptide–
lipid complexes. To reduce the membrane strains caused by the
peptide association, the peptide–lipid complexes may be forced
to retreat gradually, leaving the pores in the SLBs [50,51]. The
exposed hydrophobic pores could be stabilized by binding the
amphiphilic peptides (Fig. 9). Furthermore, since the pores are
position-steady throughout the AFM imaging (Figs. 3–6), it is
reasonable to assume that the FHDs expansion is predominantly
resulted from the semi-penetrated porations in the SLBs. Once
the pores are formed, the FHDs can expand quickly (Figs. 4–7).
Our experiments suggest the semi-penetrated poration could
be a new mode of peptide–membrane interactions, which
mediated the PrP106–126 amide diffusion into the lipid
bilayers. This distinct feature is highly consistent with the
phenomena of the decrease of the membrane fluidity but the
slightly increase of the membrane permeability caused by
PrP106–126 amide (Figs. 1 and 2).
4.2. Cholesterol and HEPES effects
The formation and expansion of FHDs induced by PrP106–
126 amide were studied in different membrane systems and
summarized in Fig. 7. In both PBS and HBS buffers, cholesterol
significantly accelerates the growing dynamics of FHDs in the
SLBs. We found that, in a visual field of the same size, thereFig. 8. (a) The depths of the pores to the top surfaces of SLBs in different
buffers. (b) Schematics of the calculation of the depth of the pore. The depth of
the pore to the top surface of the SLB (h2) is the height of the pore on the FHD
(h0) subtracts the height difference between the FHD and the SLB (h1).were more pores formed in POPC/Chl SLBs than in POPC
SLBs under the same conditions (Figs. 3–6). Also, PrP106–126
amide diffused much quicker in POPC/Chl SLBs than in POPC
SLBs as shown in Fig. 7. By retarding the dynamics of PrP106–
126 amide diffusion into POPC/Chl SLBs with HEPES, we
were able to observe that the overall diffusion process resembles
a typical “S” shaped curve with the amount of FHDs remained
at a almost unvaried low level within the first 25 min (Fig. 7).
Comparably, AFM imaging indicates that only a few pores
formed in this time period (Fig. 6). Together, these phenomena
further strengthen our hypothesis that the semi-penetrated
poration could mediate PrP106–126 amide diffusion into the
lipid bilayers.
It seemed HEPES mainly affected the initial stage of the
peptide diffusion (Fig. 7). As a zwitterionic molecule, HEPES
potentially interacts with the zwitterionic surface of the POPC
membrane and thus inhibits the adsorption of the cationic
peptide onto the SLB membrane by providing a cushion layer.
Therefore, HEPES may affect the dynamics of the PrP106–126
amide diffusion by retarding the peptide to get a threshold
concentration for the poration in the SLB membrane.
In the POPC/Chl SLB buffered by HBS, a large number of
pores were formed in a time period following the initial lag
phase, termed “mid-phase” in Fig. 7. In the mid-phase, the
FHDs expanded quickly till they filled up the visual fields.
Whereas in the SLBs without cholesterol, in the mid-phase,
there were fewer pores formed and the rates of FHDs expansion
were also slower. It implies that cholesterol may favor the
poration of the SLB thereby affects the dynamics of the peptide
diffusion.
After the treatment of PrP106–126 amide, the membrane
fluidities of POPC/Chl and POPC LUVs changed in a parallel
as well as linear fashion (Fig. 1), implicating that cholesterol
may stabilize the lipid assemblies by packing into the region of
lipid acyl chains as a spacer to increase the membrane density
[40–42], but may not provide additional thermodynamic
contributions for the peptide–membrane interactions. However,
cholesterol can also promote the phase transition and micro-
domains formation [40–42], which, we assume, could down-
regulate the threshold concentration of the peptide required for
the SLB poration. Therefore, under the same conditions, there
were more pores formed in the SLBs containing cholesterol
(Figs. 3–6).
4.3. The possible mechanisms
To our knowledge, no other research reported the semi-
penetrated poration in SLBs induced by peptides. Based on our
experiments and the above analysis, we propose three possible
poration models to illustrate the possible mechanisms of
PrP106–126 amide interacting with SLBs (Fig. 9). In model
A, the cationic as well as hydrophilic N-terminus of PrP106–
126 amide is adsorbed on the zwitterionic surface of the POPC
membrane at first, then the hydrophobic C-terminus would form
hydrophobic clusters in the membrane. This process may favor
the formation of the peptide–lipid complexes on the upper
leaflet of the SLB and increase the membrane strain. When a
Fig. 9. Schematics of the possible mechanisms of PrP106–126 amide interacting with SLBs. (A) is the major route of the peptide diffusion into SLBs mediated by the
semi-penetrated poration. The amphiphilic peptide is firstly adsorbed onto the surface of the zwitterionic membrane and associated with the upper leaflet of the SLB.
When a desired threshold concentration reaches, the membrane reduces the strain by releasing lipid–peptide vesicles and leaving the pores on the SLB. Subsequently,
via the pores, a large number of peptides diffuse into the hydrophobic region of the membrane and induce a phase transition (the formation and expansion of FHDs).
(B) The amphiphilic peptide can also insert into the zwitterionic membrane and form small sized FHDs. The vesicles of the peptide–lipid complex tend to be formed
near the small sized FHDs and result in the subsequent poration. (C) PrP106–126 amide diffuses into the hydrophobic region of the SLB via a preexisting defect on the
membrane and induces the phase transition.
1427J. Zhong et al. / Biochimica et Biophysica Acta 1768 (2007) 1420–1429desired threshold concentration of the peptide reaches, the
membrane could be relaxed through releasing the vesicles of the
peptide–lipid complex and leaving the pores in the membrane.
Subsequently, more amphiphilic peptides bind the exposed
lipids and stabilize the pores and at the same time quickly
diffuse into the lipid bilayer through the pores. It results in the
phase transition represented by the formation and expansion of
FHDs. In model B, the amphiphilic peptide can also insert
directly into the zwitterionic membrane at a specific orientation,
in which the peptide–lipid complexes cannot be released. As a
consequence, only small sized FHDs appear and grow slowly.
While nearby, the packing of the lipids could be disturbed so as
to adapt the phase transition and later on, the peptide–lipid
complex vesicles are formed and released. Subsequently, more
and more of the peptide molecules diffuse into the lipid bilayer
through the pores. Model C shows the poration is originated
from the defects on the membrane, which could be occurred
during the bilayers preparation or AFM imaging, but they are
rarely observed in the experiments.
Although our experiments were performed on the simple
lipid bilayers, we were able to observe the distinct patterns of
the retarded peptide–membrane interactions by using the C-amidated PrP106–126. It implicates that the neurotoxicity of the
pathogenic PrPSc in real cells could be related to the specific
membrane disturbance to a certain extent. Given the phenomena
of the semi-penetrated poration and the FHDs expansion, the
integrity and functions of cell membranes could be severely
disrupted, and some membrane proteins could also be affected
in a way. Further studies to address the exact locations of the
peptide by fluorescence microscopy would help to unveil the
detailed molecular basis of the membrane perturbation of
PrP106–126. On the other hand, investigations of the changes
of the lipid structure/phase and the microdomains on mem-
branes may provide more information on the peptide–
membrane interactions.
4.4. Investigating peptide–lipid interaction by in situ time-lapse
AFM
In situ time-lapse AFM is a powerful tool for studying
biomolecules interacting with SLBs [26,52,53]. Generally,
AFM has the following advantages of imaging the interactions
of macromolecules: (1) the processes of biological interactions
can be visualized under the physiological conditions; (2) it has a
1428 J. Zhong et al. / Biochimica et Biophysica Acta 1768 (2007) 1420–1429high spacial resolution (in sub-nanometer range); (3) interac-
tions can be monitored in time-lapse experiments; (4) unlike
other techniques, samples can be viewed in their native states
without complicate preparations and chemical modifications.
However, the poor temporal resolution (in minute range) greatly
limits the AFM applications. To overcome such limitation,
zwitterionic agents such as HEPES may be used in experiments
to retard some biological interactions. Notably, confocal-atomic
force microscopy, which has high temporal and spatial
resolutions, is being exploited successfully in tracking the
peptide–membrane interactions [50,54].
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